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Background-—Transient receptor potential melastatin member 4 (TRPM4) is a nonselective cation channel. TRPM4 mutations have
been linked to cardiac conduction disease and Brugada syndrome. The mechanisms underlying TRPM4-dependent conduction
slowing are not fully understood. The aim of this study was to characterize TRPM4 genetic variants found in patients with
congenital or childhood atrioventricular block.
Methods and Results-—Ninety-one patients with congenital or childhood atrioventricular block were screened for candidate genes.
Five rare TRPM4 genetic variants were identiﬁed and investigated. The variants were expressed heterologously in HEK293 cells. Two of
the variants, A432T and A432T/G582S, showed decreased expression of the protein at the cell membrane; inversely, the G582S
variant showed increased expression. Further functional characterization of these variants using whole-cell patch-clamp conﬁguration
showed a loss of function and a gain of function, respectively. We hypothesized that the observed decrease in expression was caused
by a folding and trafﬁcking defect. This was supported by the observation that incubation of these variants at lower temperature
partially rescued their expression and function. Previous studies have suggested that altered SUMOylation of TRPM4may cause a gain
of function; however, we did not ﬁnd any evidence that supports SUMOylation as being directly involved for the gain-of-function variant.
Conclusions-—This study underpins the role of TRPM4 in the cardiac conduction system. The loss-of-function variants A432T/
G582S found in 2 unrelated patients with atrioventricular block are most likely caused by misfolding-dependent altered trafﬁcking.
The ability to rescue this variant with lower temperature may provide a novel use of pharmacological chaperones in treatment
strategies. ( J Am Heart Assoc. 2016;5:e001625 doi: 10.1161/JAHA.114.001625)
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C ongenital and childhood atrioventricular block (AVB)
1 is
characterized by a delay or interruption in the impulse
transmission from the atria to the ventricles caused by either
anatomical or functional impairment in the conduction system
that is observed at birth or at a young age. Conduction can be
delayed, intermittent, or absent, and the conduction distur-
bances can be transient or permanent. Implantation of a
pacemaker is the main therapeutic option for congenital AVB.
In young patients, congenital AVB could be caused by either
(1) acquired autoimmune disease in which maternal autoan-
tibodies against the intracellular ribonucleoproteins Ro/SSA
and La/SSB cross the placenta and inhibit L-type calcium
channels2,3 or (2) genetic variants in NKX2.5,4,5 SCN5A, and
SCN1B genes coding for the homeobox protein Nkx-2.5, the
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voltage-gated sodium channel Nav1.5, and the auxiliary
subunit b1 of the voltage-gated sodium channel, respec-
tively.5–7 Recently, at least 10 genetic variants in the transient
receptor potential channel melastatin 4 (TRPM4) gene have
been linked to different forms of cardiac conduction defect
and Brugada syndrome (BrS).8–11 The ion channel TRPM4 is a
member of the transient receptor potential channel family,
which comprises at least 28 genes in the human genome.
TRPM4 is an intracellular Ca2+-activated nonspeciﬁc cation
channel that is not permeable to Ca2+ and is expressed in
different cells of the cardiovascular system, such as arterial
and venous smooth muscle cells and cardiac cells of the
conduction pathways.8,12–14 As with all transient receptor
potential channels, each monomer contains 6 transmem-
brane-spanning segments, whereas the channel pore is
formed by a tetramer. The cellular response on TRPM4
activation or inactivation depends on the cell type and the
coexpression of membrane transporters. Its activation
enables Na+ entry into the cell, leading to cellular membrane
depolarization. TRPM4 also participates in intracellular Ca2+
sensing and affects the driving force for Ca2+ and other ions
by altering the cellular membrane electrical potential.
In a seminal study,8 the E7K TRPM4 variant was found to
be linked to progressive familial type 1 heart block in a large
South African pedigree. Characterization of this variant
demonstrated that it led to a gain of expression at the cell
membrane as well as a gain of function. Further experiments
suggested that increased SUMOylation of this variant might
be the cause of the observed gain of function. The molecular
details of these alterations, however, remain poorly under-
stood. Other TRPM4 variants causing either gain or loss of
function have been found in patients with autosomal-
dominant cardiac conduction disease,9 different forms of
cardiac conduction alterations,10 and BrS.11 Although the
study by Kruse et al8 clearly linked TRPM4 to conduction
block based on genetic linkage, more recent studies have
failed to demonstrate a direct relationship between the
sporadic presence of the variants and the electric pheno-
types.10 It has been proposed that these TRPM4 variants may
act as modiﬁers in the context of a complex genetic
background.10 Furthermore, how both gain- and loss-of-
function variants may lead to conduction slowing has yet to
be determined.15
In the present study, we identiﬁed 5 rare variants in the
TRPM4 gene of patients with either congenital or childhood
AVB. Additional functional and biochemical characterization of
these variants identiﬁed 2 with loss of function and 1 with
gain of function. We further examined the possible mecha-
nisms by which these variants could have altered plasma
membrane expression. Moreover, this work also assessed the
possibility of rescuing the loss-of-function variants and
restoring their membrane expression and function.
Material and Methods
The study involving humans conforms to the guiding
principles of the Declaration of Helsinki. Human subjects
gave informed consent for a study that was approved by the
Institutional Committee on Human Research at the authors’
institution.
Samples
A total of 91 unrelated patients and their parents were
identiﬁed from a multicenter retrospective study from 1980
to 2009 carried out in 13 French tertiary hospitals.16 Patients
were included in the study if they had AV conduction
disturbance with negative maternal anti-Ro/SSA and anti-La/
SSB antibodies and without associated structural cardiac
malformation. Patients born before 1980 were excluded
because of the major progress in prenatal diagnosis and
neonatal management of AVB and in pacing technologies.
Both incomplete and complete AVB were considered.
Patients with traumatic or postoperative heart block were
excluded, as were those with myocarditis, neuromuscular
disorders, metabolic diseases, congenital structural heart
disease likely to account for AVB, and long QT syndrome.
Mothers of included patients were all screened for maternal
antibodies to soluble nuclear antigens 48-kDa SSB/La, 52-
kDa SSA/Ro, and 60-kDa SSA/Ro using quantitative radioli-
gand assays. In case of missing data or negative maternal
antibodies diagnosed with a less sensitive technique, parents
were contacted and rescreened with radioligand assays.
Written informed consent was obtained from all participants
or their guardians. For each patient, standard 12-lead ECGs
were collected at time of diagnosis and at time of pacemaker
implantation or at last follow-up if not implanted. ECGs were
analyzed by 2 blinded medical investigators, and interval
durations were measured using dedicated Datinf Measure
software (Datinf). The earliest documentation of a conduction
abnormality of a patient was used as the time of diagnosis of
AVB. Type of block, heart rate, PR intervals, QRS complexes,
and QT interval durations were determined. QT interval
measurement was adjusted to the heart rate using the Bazett
formula.17 Among these 91 children, 15 showed congenital
AVB (6 were diagnosed in utero) and 76 had childhood AVB.
The median age at diagnosis was 24 months. Different types
of conduction block were diagnosed: (1) 3 cases of AVB type
1, (2) 21 cases of AVB type 2 (23%) (8 Mobitz type 1 and 13
Mobitz type 2), and (3) 67 cases of complete AVB (73.6%).
The majority (84.6%) of QRS complex durations were not
increased, whereas intraventricular conduction abnormalities
were observed in 14 children (15.4%), distributed in 7 blocks
of right bundle branch (3 complete and 4 incomplete), 5 left
bundle branch block (3 complete and 2 left anterior
hemiblock), 1 alternation between right bundle branch and
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left bundle branch block, and 1 case of undetermined
complete block. Implantation of a pacemaker was required in
73 children (80.2%) during a median follow-up of 9.5 months.
Mutation Screening
Genomic DNA was extracted from peripheral blood by using
the NucleoSpin Blood XL kit (Macherey-Nagel), as described
by the manufacturer. NKX2.5, SCN5A, SCN1B, and 10 coding
exons of TRPM4 (ENSG00000130529, ENST00000252826)
were screened by direct DNA sequencing, and 15 coding
exons of TRPM4 were screened by high-resolution melting
curve analysis in all patients. The primers were designed to
ﬂank the coding regions. Polymerase chain reaction (PCR) and
high-resolution melting were performed in a single run on a
LightCycler 480 instrument (Roche Diagnostics). The high-
resolution melting analysis was performed using Gene
Scanning software version 1.5.0 (Roche Instrument Centre),
which allows for clustering of the samples into groups on the
basis of difference plots obtained by analyzing the differences
in melting curve shapes. All samples studied were clustered at
the default sensitivity setting (0.5). Samples with an aberrant
melting proﬁle were assigned for validation sequencing to
identify or exclude sequence variants. Forward- and reverse-
sequence reactions were performed with the BigDye Termi-
nator v3.1 Cycle Sequencing Kit (Applied Biosystems) using
the same primers. The sequence products were analyzed on a
3730 DNA Analyzer (Applied Biosystems).
Molecular Cloning
The following TRPM4 variants were selected for molecular
cloning: p.D198G, p.A432T, p.G582S, p.T677I, and p.V921I.
Constructions were called, respectively, D198G, A432T,
G582S, T677I, and V921I, and the double variant (p.A432T/
p.G582S) was called A432T/G582S. The cDNA of TRPM4 was
obtained in 2 overlapping fragments from human kidney RNA
(Stratagene, Amsterdam, Netherlands) by reverse transcrip-
tion with Mu-MLV reverse transcriptase (Eurogentec France
SASU). The complete TRPM4 cDNA was cloned in pcDNA4/
TO vector (Invitrogen). It was provided by A. Guse (University
Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany)
and P. Bouvagnet (Laboratoire Cardiogenetique, Hospices
Civils de Lyon, Groupe Hospitalier Est, Bron, France). TRPM4
p.E7K mutant (called TRPM4 E7K) was provided by
P. Bouvagnet.
Primers for reverse transcription and PCR are available on
request. Mutant TRPM4 cDNAs were obtained by in vitro
mutagenesis using the QuickChange XLII site-directed muta-
genesis kit (Stratagene). Mutagenesis primer sequences are
available on request. Mutant cDNA clones were systematically
sequenced before use in further experiments.
Cell Culture and Transfection
Human embryonic kidney (HEK293) cells were cultured with
DMEM supplemented with 4 mmol/L glutamine, 10% FBS,
and 20 lg/mL gentamycin. They were transiently transfected
with 240 ng of HA-TRPM4 wild type (WT), variants (D198G,
A432T, G582S, A432T/G582S, T677I and V921I), or empty
vector (pcDNA4TO) in a P100 dish (BD Falcon), mixed with
30 lL of JetPEI (Polyplus-transfection) and 250 lL of
150 mmol/L NaCl. The cells were incubated for 48 hours at
37°C with 5% CO2. The amount of cDNA used was propor-
tionately increased to the amount used for electrophysiolog-
ical studies. For electrophysiological studies, T25 25-cm2
ﬂasks of HEK293 cells were transiently cotransfected using
X-tremeGENE 9 DNA transfection mix reagent (Roche Diag-
nostics) with 80 ng WT or variant TRPM4 channels. All
transfections included 200 ng cDNA encoding CD8 antigen as
a reporter gene. Anti-CD8 beads (Dynal) were used to identify
transfected cells, and only CD8-displaying cells were ana-
lyzed. Cells were used 48 hours after transfection.
Real-Time Quantitative PCR
RNA isolation was performed with the NucleoSpin RNA II kit
(Macherey-Nagel), as described by the manufacturer. Using
cDNAs of transfected HEK293 cells, we performed quantita-
tive expression analysis with the 7900HT Fast Real-Time
PCR System (Applied Biosystems). The PCR ampliﬁcation
was performed with TaqMan gene expression assay
Hs01026070_m1 for human TRPM4. For control, we studied
expression of a cotransfected human CD8 gene with TaqMan
gene expression assay Hs00233520_m1. For each sample,
triplicate determinations were performed in a 96-well optical
plate using 80 ng of cDNA, 1 lL of 209 TaqMan Gene
Expression Assay, 10 lL of 29 TaqMan Fast Universal PCR
Master Mix No AmpErase UNG, and 5 lL of water in each
20 lL reaction. Plates were heated for 20 seconds at 95°C,
and then 40 cycles of 1 second at 95°C and 20 seconds at
60°C were applied. Relative TRPM4 expression (DCt) was
calculated by subtracting the signal threshold cycle (Ct) of the
control (CD8) from the Ct value of TRPM4. Subsequently,
DDCt values were obtained for each mutant by subtracting
the DCt of the TRPM4 WT from the DCt of each mutant.
Results were then linearized by calculating 2expDDCt.
Cell Surface Biotinylation Assay
Following 48 hours of incubation, transiently transfected
HEK293 cells were treated with EZ-Link Sulfo-NHS-SS-Biotin
(Thermo Scientiﬁc) 0.5 mg/mL in cold 19 PBS for 15 min-
utes at 4°C. Subsequently, the cells were washed twice with
200 mmol/L glycine in cold 19 PBS and twice with cold 19
PBS to inactivate and remove excess biotin, respectively. The
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cells were then lysed with 19 lysis buffer (50 mmol/L HEPES,
pH 7.4; 150 mmol/L NaCl; 1.5 mmol/L MgCl2; 1 mmol/L
EGTA, pH 8.0; 10% glycerol; 1% Triton X-100; 19 Complete
Protease Inhibitor Cocktail [Roche]) for 1 hour at 4°C. Cell
lysates were centrifuged at 16 000g at 4°C for 15 minutes.
Next, 2 mg of the supernatant were incubated with 50 lL
Streptavidin Sepharose High Performance beads (GE Health-
care) for 2 hours at 4°C, and the remaining supernatant was
kept as input. The beads were subsequently washed 5 times
with 19 lysis buffer before elution with 50 lL of 29 NuPAGE
sample buffer (Invitrogen) plus 100 mmol/L DTT at 37°C for
30 minutes. These biotinylated fractions were analyzed as
TRPM4 expressed at the cell surface. The input fractions,
analyzed as total expression of TRPM4, were resuspended
with 49 NuPAGE Sample Buffer plus 100 mmol/L DTT to give
a concentration of 1 mg/mL and incubated at 37°C for
30 minutes.
Immunoprecipitation
Transiently transfected HEK293 cells in P100 plates were
harvested after 48 hours of incubation and lysed with 19
cold Ubi lysis buffer (50 mmol/L HEPES, pH 7.4; 150 mmol/
L NaCl; 1 mmol/L EGTA, pH 8.0; 10% glycerol; 19 EDTA-free
Complete Protease Inhibitor Cocktail [Roche]; 2 mmol/L
N-ethylmaleimide/NEM [Sigma-Aldrich], 10 mmol/L iodoac-
etamide/IAA [Sigma-Aldrich]) containing 1% Triton X-100 for
1 hour at 4°C. Cell lysates were then centrifuged at 16 000g
at 4°C for 15 minutes. Next, 2 mg of the supernatant (lysate)
were incubated at 4°C for 24 hours with 10 lg anti-
RanGAP1 A302-027A (Bethyl Laboratories) or 20 lg anti-
HA MMS-101R (Covance) to immunoprecipitate RanGAP1
and HA-tagged TRPM4, respectively. One volume of 19 cold
Ubi lysis buffer without Triton X-100 (to obtain a ﬁnal
concentration of 0.5% Triton X-100) was also added in the
mix. On the next day, the lysate–antibody mix was
transferred to a microcentifuge tube containing 50 lL (1:1
bead:lysis buffer ratio) of Protein G Sepharose beads (GE
Healthcare), which were previously washed 3 times with 19
cold Ubi lysis buffer containing 0.5% Triton X-100. After
adding fresh 19 EDTA-free Complete Protease Inhibitor
Cocktail, the mix was incubated overnight at 4°C. The beads
were subsequently washed 5 times (4°C; 0.8 g) with 19 cold
Ubi buffer containing 0.3% Triton X-100 before elution with
50 lL of 29 NuPAGE sample buffer plus 100 mmol/L DTT
at 37°C for 30 minutes. These samples are designated as
immuniprecipitation fractions. The input fractions were
resuspended with 49 NuPAGE Sample Buffer plus
100 mmol/L DTT to give a concentration of 1 mg/mL and
incubated at 37°C for 30 minutes. All lysis and incubation
steps, except elution in sample buffer, were performed in
absence of light.
Low-Temperature Rescue Experiments
HEK293 cells were transiently transfected individual TRPM4 WT
or TRPM4 variants (A432T, A432T/G582S). After the ﬁrst
24 hours of incubation at 37°C (95% O2 and 5% CO2), 1 set of
transfected HEK293 cells was kept in the same incubator, and
another set was shifted to a 28°C incubator supplied with 95% O2
and 5% CO2 for 24 hours. The following day, cell surface
biotinylation assay (as described earlier in Cell Surface Biotinyla-
tion Assay) was performed on the 2 sets of HEK293 cells.
Generation of glutathione-S-transferase (GST) and
GST-S5a and Pull-Down Experiments
Glycerol stocks of Escherichia coli DH5a transformed with
pGEX-4T3 (GST alone) and pGEX-S5a were added to 1 L Luria-
Bertan medium containing ampicillin (0.1 lg/lL) and grown to
an OD600 of 0.600. The bacterial cultures were then induced
with 1 mmol/L IPTG for 2.5 hours at 29°C. Cells were
harvested by centrifugation (800 g, 4°C, 15 minutes in a
Sorvall Legend RT+ benchtop centrifuge), resuspended in
25 mL 19 bacterial lysis buffer (0.5 mol/L Tris, pH 7.5;
2.5 mol/L NaCl; 10% Igepal; and 19 Complete Protease
Inhibitor Cocktail Roche, IN, USA), added with 0.2 mg/mL
lysozyme and then mixed by gently inverting the tube several
times until it appeared viscous. The mix was then neutralized by
adding 10 mmol/L MgSO4 and sonicated 3 times for 10 sec-
onds each at 100% power (with 10-second breaks in between)
to disrupt DNA. To obtain protein lysate, the mix was
transferred to a Sorvall tube and centrifuged in an ss-43 rotor
for 10 minutes at 11 200 g at 4°C. Protein lysate was then
transferred to a falcon tube and combined with 3 mL of
glutathione-sepharose beads (GE Healthcare Biosciences)
previously washed with distilled water and 19 bacterial lysis
buffer and rotated on a wheel at 4°C for 2 hours to facilitate
binding. The mix was then washed 5 times with 15 mL 19
bacterial lysis buffer (4°C, 10 minutes at 0.1 g in a Sorvall
Legend RT+ benchtop centrifuge). After the concentration of
GST fusion protein/glutathione–sepharose complex was deter-
mined, it was stored in glycerol buffer at 80°C. Transiently
transfected HEK293 cells in P100 plates were harvested after
48 hours of incubation and lysed with 19 cold Ubi lysis buffer
(50 mmol/L HEPES, pH 7.4; 150 mmol/L NaCl; 1 mmol/L
EGTA, pH 8.0; 10% glycerol; 19 EDTA-free Complete Protease
Inhibitor Cocktail; 2 mmol/L NEM) containing 1% Triton X-100
for 1 hour at 4°C. Cell lysates were then centrifuged at
16 000g at 4°C for 15 minutes. Next, 1 mg of the supernatant
(lysate) was incubated with 100 lg GST or GST-S5a coupled on
glutathione beads at 4°C for 2 hours. The beads were
subsequently washed 5 times (4°C; 0.8 g in a tabletop
centrifuge) with the same 19 cold Ubi buffer described above
except containing 0.5% Triton X-100 before elution with 50 lL
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29 NuPAGE sample buffer plus 100 mmol/L DTT at 37°C for
30 minutes. These samples are designated as pull-down
fractions. The input fractions were resuspended with 49
NuPAGE Sample Buffer plus 100 mmol/L DTT to give a
concentration of 1 mg/mL and incubated at 37°C for 30 -
minutes.
Western Blotting Experiments
Protein samples were analyzed on 9% polyacrylamide gels,
transferred with the TurboBlot dry blot system (Bio-Rad), and
detected with anti-TRPM4 (generated by Pineda), anti-
RanGAP1 A302-026A (Bethyl Laboratories), anti-SUMO1
S8070 (Sigma-Aldrich), anti-SUMO2/3 ab3742 (Abcam),
anti-Na+/K+ ATPase a1 ab7671 (Abcam), and anti–a-actin
A2066 (Sigma-Aldrich) antibodies using SNAP id (Millipore).
The anti-TRPM4 antibody was generated by Pineda using the
following peptide sequence: NH2-CRDKRESDSERLKRTSQKV-
CONH2. A fraction of the antisera, which was subsequently
used in this study, was then afﬁnity puriﬁed.
Cellular Electrophysiology
For patch-clamp experiments in whole-cell conﬁguration,
intracellular solution contained (in mmol/L) 100 CsAsp, 20
CsCl, 4 Na2ATP, 1 MgCl2, 10 EGTA, and 10 HEPES. The pH was
adjusted to 7.20 with CsOH and the free Ca2+ concentration at
100 lmol/L with CaCl2, using the WEBMAXCLITE program
(http://www.stanford.edu/cpatton/downloads.htm). Na2ATP
has been added to the intracellular solution to be as close as
possible to physiological cytosolic solution and to provide
phosphate residue for phosphorylation processes. Extracellular
solution contained (in mmol/L) 156 NaCl, 1.5 CaCl2, 1 MgCl2, 6
CsCl, 10 glucose, and 10 HEPES. The pH was adjusted to 7.40
with NaOH. Patch-clamp recordings were carried out in the
whole-cell conﬁguration at room temperature. TRPM4 currents
were investigated using a ramp protocol. The holding potential
was 60 mV. The 400-ms increasing ramp from 100 to
+100 mV ended with a 300-ms step at +100 mV and then
300 ms at 100 mV. A new ramp was performed every
2 seconds. Current densities were obtained by dividing the
peak current recorded at 100 mV by the cell capacitance.
Statistical Analysis
Data are presented as the meanSEM. The unpaired 2-tailed
Student t test was used to compare the means, with P<0.05
considered signiﬁcant. For the experiments, the WT condition
was used as the reference for normalization and quantiﬁca-
tion. The P values were not correct for multiple testing
because each variant was compared with the WT allele only
and not between variants.
Results
Genetic Screening in Patients With Congenital
AVB
All exons of the NKX2.5, SCN5A, SCN1B, and TRPM4 genes
were directly sequenced or screened using high-resolution
melting in a cohort of 91 pediatric patients (Table 1) with
congenital (n=15) or childhood (n=76) AVB (Figure 1). The
genes already identiﬁed in cardiac conduction diseases were
screened initially (ie, NKX2.5, SCN5A, and SCN1B) (Table 2).
A nonsynonymous variant was identiﬁed in NKX2.5 (A119S)
(Table 2). This variant was detected in a boy with complete
AVB that was diagnosed when he was aged 5 years, and a
pacemaker was implanted when he was aged 11 years. This
A119S mutation was described previously in a patient with
severe hypothyroidism.18 A nonsynonymous variant was
identiﬁed in SCN1B (C211Y) in a young boy with complete
AVB diagnosed at age 18 months, and a pacemaker was
implanted at age 30 months. A frame shift variant was
identiﬁed in SCN5A (T1806SfsX27) in a girl with ﬁrst-degree
AVB diagnosed at age 7 years. This child, with a follow-up of
4 years, was never implanted with a pacemaker (Table 2).
TRPM4 was screened in this cohort (Table 2) because 4
recent studies have reported variants in TRPM4 in patients
with cardiac conduction disease and BrS.8–11 We identiﬁed 10
TRPM4 variants in 14 patients, and 3 of those variants were
already reported in familial cases of progressive cardiac
conduction disease (A432T, G582S, and G844D)9,10 (Table 2).
The G582S variant was found to be isolated only with A432T
variants in 2 patients belonging to 2 unrelated families
(Table 2). Two of the 10 TRPM4 variants were previously
classiﬁed as polymorphisms (P1204L and K487L498del)8
because of their frequencies in control populations, whereas 5
nonsynonymous variants were never previously described
(D198G, R252Q, T677I, G737R, V921I) (Table 2).
Pathogenicity Assessment of TRPM4 Variants
Allele frequency was evaluated in a cohort of controls. The
results are shown in Table 2. Five variants with an allele
frequency ≥0.1% were classiﬁed as polymorphisms and were
excluded from functional analysis (R252Q, K487L498del,
G737R, G844D and P1204L) (Table 2). Five rare variants with
a frequency ≤0.1% (D198G, A432T, G582S, T677I, and V921I),
found in conserved regions of TRPM4 (Figure 2), were
subjected to biochemical and functional investigations.
The Double Variant: A432T/G582S
The TRPM4 mutant A432T was shown previously to generate
a gain of function.9 In the present study, we identiﬁed 2
unrelated patients with this variant (Figures 1 and 3). In
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contrast to the former study,9 these patients also had a
second variant, G582S (Figure 1), on the same haplotype.
Functional studies were simultaneously performed on A432T,
G582S, and A432T/G582S to evaluate the impact of the
individual variants on TRPM4 function. These 2 patients also
carried NKX2.5 and SCN5A variants in their genomes, as
described earlier (Table 2).
TRPM4 Variants Show Different Protein
Expression Levels
We assessed whether the TRPM4 variants have any effect on
protein expression when expressed transiently in HEK293
cells. We performed cell surface biotinylation experiments to
determine whether they affect TRPM4 expression at the cell
membrane. As reported previously,19 we observed that WT
and TRPM4 variants were expressed in fully and core-
glycosylated forms (Figure 4A). We expressed the E7K variant
to serve as a control. The E7K variant was reported previously
in a family with a cardiac conduction defect8 and was shown
to lead to increased expression levels in HEK293 cells.8 As
illustrated in Figure 4A and 4B, we also observed increased
expression at the cell membrane for the E7K variant
(18426% of WT; quantiﬁcation done on 4 different Western
blots), and the 2 variants A432T and A432T/G582S showed
decreased expression (28.84.5% and 16.56.9% of WT,
respectively; quantiﬁcation done on 4 different Western
blots). Interestingly, the variant G582S alone showed an
increase in expression (176.515% of WT; quantiﬁcation done
on 4 different Western blots), whereas the variants D198G,
T677I, and V921I showed no signiﬁcant changes in expres-
sion (Figure 4A and 4B) (quantiﬁcation done on 4 different
Western blots). We performed real time-PCR experiments to
determine whether these differences may have been caused
by variable mRNA levels; however, no signiﬁcant differences
were observed (data not shown).
Electrophysiological Properties of TRPM4
Variants Involved in AVB
As recently reported using the patch-clamp technique in
whole-cell conﬁguration with HEK293 cells,20 TRPM4 currents
recorded over time showed 2 distinct phases (Figure 5A).
There is a transient phase of approximately <1 minute that
appears quickly after the rupture of the membrane patch, and
a steady plateau phase that appears 4 to 8 minutes later
(Figure 5A). To investigate the functional consequences of the
TRPM4 variants, we measured the transient and plateau
current densities using a ramp protocol (Figure 5A). The
transient phase showed widely variable current amplitudes,
possibly because of a known phenomenon of channel
desensitization.21,22 We considered the more stable plateau
phase for further functional analysis. We observed decreased
current density with the variant A432T (424% of WT; WT,
n=20, and A432T, n=6; P<0.05) and increased current density
with the variants G582S (17120% of WT; WT, n=20, and
Table 1. Clinical and ECG Characterizations of Congenital and Childhood Atrioventricular Block Patients
Total Without TRPM4 Variants With TRPM4 Variants
General characterizations
Number of children 91 77 14
Mean age at diagnosis, months 43.948.0 45.048.9 37.344.3
Median age at diagnosis, months 24 (in utero 228) 24 (in utero 228) 12 (in utero 126)
Congenital atrioventricular block, % 16.5 13.0 35.7
Childhood atrioventricular block, % 83.5 87.0 64.3
ECG characterizations
Complete atrioventricular block, % 73.6 67.8 78.6
Intraventricular conduction disorder, % 15.4 11.7 35.7
Heart beat, bpm 56.016.4 56.016.0 54.019.5
QRS duration, ms 80.028.8 79.028.5 88.031.1
QT interval corrected, ms 433.167.1 427.045.3 469.0143.7
Pacemaker implant
Pacemaker implant, % 80.2 77.9 92.8
Mean age at implant, months 69.261.6 72.662.0 53.959.6
Median age at implant, months 54 (0–264) 54 (0–264) 24 (0–338)
Median time between diagnosis and implantation, months 9.5 (0–144) 12.0 (0–144) 0.0 (0–102)
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G582S, n=6; P<0.05) and E7K (23846% of WT; WT, n=20,
and E7K, n=6; P<0.05). The rest of the variants did not show
any signiﬁcant changes in current densities in comparison to
WT (WT, n=20; D198G, n=6; A432T/G582S, n=5; T677I, n=5;
and V921I, n=5) (Figure 5B and 5C).
No Evidence of Direct SUMOylation of TRPM4
In the initial report linking TRPM4 to cardiac conduction
defects,8 it was proposed that the gain of function
demonstrated by the E7K variant, observed as increased
protein expression and current density, was caused by
augmentation of channel SUMOylation. A variant in the
present study, G582S, also showed increased expression at
the plasma membrane (Figure 4B) and current density
(Figure 5C). We performed immunoprecipitation experiments
and subsequent Western blots using anti-SUMO1 and anti-
SUMO2/3 antibodies to investigate its SUMOylation status.
The Ran GTPase-activating protein 1 (RanGAP1) was used as a
positive control because it is a well-known protein that is
A
B
Figure 1. Families with AVB. A, Pedigrees of families with members harboring TRPM4 variants. B,
Illustration of the TRPM4 channel showing the location of the 5 congenital atrioventricular block variants
described in this study. The dashed box highlights the presence of 2 variants in the same patient. AVB
indicates atrioventricular block.
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SUMOylated with SUMO1, SUMO2, and SUMO3.23 As illus-
trated in Figure 6A, RanGAP1 (left panel) and both TRPM4 (WT
and G582S; right panel) were immunoprecipitated. RanGAP1
showed a doublet, corresponding to its SUMOylated
(90 kDa) and non-SUMOylated (70 kDa) forms.24 The
immunoprecipitated RanGAP1 and TRPM4 were then blotted
with anti-SUMO1 and anti-SUMO2/3. As shown in Figure 6B,
RanGAP1 showed clear signals for anti-SUMO1 (upper panel)
and anti-SUMO2/3 (lower panel) at 90 kDa, whereas
TRPM4 WT and the mutant G582S did not (Figure 6B). Based
on these results, we came to the conclusion that TRPM4 is
not directly SUMOylated with SUMO1, SUMO2, or SUMO3.
Because Ubc9 is the E3 ligase responsible for SUMOyla-
tion,8,9 we tested whether this enzyme was able to increase
the current density of WT TRPM4, as previously shown by
Kruse et al.8 As seen in Figure 6C, the coexpression of Ubc9
increased the TRPM4 current density by 3-fold (WT, n=8, and
Ubc9, n=5; P<0.05). Nevertheless, because a similar increase
was observed with the catalytic inactive mutant (Ubc9*) of
the E3 ligase, we concluded that this effect was not
dependent on the SUMOylation activity of the protein (WT,
n=8, and Ubc9*, n=5; P<0.05). These experiments suggest
that direct SUMOylation of TRPM4 is unlikely to be linked to
the increased expression and gain of function of the TRPM4
G582S variant.
TRPM4 Loss-of-Function Variants Are Rescued by
Incubation at Low Temperature
TRPM4 variants A432T and A432T/G582S showed reduced
protein expression at the cell membrane, a phenomenon that
has not been reported previously (Figure 4B). Because
decreased expression may be a result of protein misfolding,
we tested whether lowering the incubation temperature could
possibly rescue the misfolded membrane proteins and restore
their expression at the cell surface, as already shown by the
Table 2. Clinical and Genetic Features From Patients Carrying Rare TRPM4 Variants
Patients TRPM4 Variants
Variant Frequency in
ExAc (Controls)
No. Age and Rhythm at Diagnosis Age and Rhythm at Implantation Exon Nucleotide Amino Acid European
1 10.5 years Complete AVB 13 years Complete AVB 05 c.593A>G p.Asp198Gly 0
2 6 months AVB1
AVB2
Type 1
9 years Complete AVB 06 c.755G>A p.Arg252His 0.0082
3* 5 years Complete AVB 11 years Complete AVB 11
13
c.1294G>A
c.1744G>A
p.Ala432Thr
p.Gly582Ser
0.0005
0.0006
4* 7 years First-degree AVB No pacemaker — 11
13
c.1294G>A
c.1744G>A
p.Ala432Thr
p.Gly582Ser
0.0005
0.0006
5 6 years Complete AVB 9 years Complete AVB 11 c.1458_1493del36 p.Lys487_Leu498del 0
6 4 months Complete AVB 5 months Complete AVB 15 c.2030C>T p.Thr677Ile 0
7 In utero
33 weeks
of gestation
Complete AVB 3 days Complete AVB 16 c.2209G>A p.Gly737Arg 0.0017
8 In utero
36 weeks
of gestation
Complete AVB 1 day Complete AVB 17 c.2531G>A p.Gly844Asp 0.0044
9 At birth Complete AVB 3 days Complete AVB 17 c.2531G>A p.Gly844Asp 0.0044
10 8.5 years Complete AVB 8.5 years Complete AVB 17 c.2531G>A p.Gly844Asp 0.0044
11 At birth Complete AVB 2 days Complete AVB 17 c.2531G>A p.Gly844Asp 0.0044
12 In utero
38 weeks
of gestation
Complete AVB 1 day Complete AVB 17 c.2531G>A p.Gly844Asp 0.0044
13 18 months AVB1
AVB 2/1
2 years Complete AVB 18 c.2761G>A p.Val921Ile 0.0001
14 5 years Complete AVB 5.5 years Complete AVB 24 c.3611C>T p.Pro1204Leu 0.0051
TRPM4 genotypes and their respective allele frequencies in controls are presented for 14 congenital AVB cases. Age and rhythm at diagnosis and pacemaker implantation are presented for
each patient. (1) c.355G>T, p.A119S. (2) c.5415_5418del415 p.Thr1806SerfsX27. AVB indicates atrioventricular block; ExAc, Exome Aggregation Consortium.
*Patients 3 and 4 also harbor NKX2.5 and SCN5A point mutations, respectively.
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others.25 As illustrated in Figure 7A, lowering the incubation
temperature of cells expressing the variants to 28°C for
24 hours increased their expression both at the total level
(A432T 783% and A432T/G582S 695% of WT; quantiﬁca-
tion done on 3 different Western blots) and at the cell surface
level (A432T 728% and A432T/G582S 657% of WT;
quantiﬁcation done on 3 different Western blots). This partial
rescue was also observed at the functional level with a
signiﬁcant increase in the current density of A432T
(599104 pA/pF [n=6] at 28°C versus 23027 pA/pF
[n=6] at 37°C; P<0.05), whereas WT showed no signiﬁcant
change (639101 pA/pF [n=4] at 28°C versus 55374 pA/
pF [n=6] at 37°C; P>0.05) (Figure 7B).
A Fraction of TRPM4 Protein Is Ubiquitylated
As presented in Figure 7, protein misfolding seems to be
involved in decreased protein levels of selected TRPM4
variants. It may be postulated that the ubiquitylation–
proteasome system might also play a role in this phe-
nomenon.26 To see whether TRPM4 can be ubiquitylated, we
performed a GST pull-down experiment using GST-S5a, a GST-
tagged proteasome subunit that recognizes ubiquitylated
proteins.27 With this GST-S5a, we were able to pull down bulk
ubiquitylated proteins that were otherwise absent when pulled
down with GST only (Figure 8A). As presented in Figure 8A,
the pull-down fractions showed bands that correspond to
TRPM4 when revealed with antibody against TRPM4; however,
quantiﬁcation of input and pull-down fractions did not show
any signiﬁcant difference between the 2 fractions for the WT
and mutant TRPM4 channels (Figure 8B) (quantiﬁcation done
on 3 different Western blots). Our results suggest a fraction of
TRPM4 to be ubiquitylated; however, we did not observe any
further increase in the ubiquitylation to explain the loss-of-
function variants.
Discussion
The study had several main ﬁndings. First, the study identiﬁed
5 rare variants in the gene encoding TRPM4 channel in
patients with congenital or childhood AVB. Second, functional
Figure 2. Human, mouse, and rat TRPM4 sequence alignments and localization of variants described in this study.
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and expression studies in a heterologous expression system
identiﬁed 2 of these variants, A432T and A432T/G582S, with
loss of function and variant G582S with gain of function.
Third, unlike previous reports, we did not ﬁnd any evidence to
conﬁrm a direct or indirect role of SUMOylation in the gain-
of-function TRPM4 variants. Fourth, the loss-of-function
TRPM4 variants could likely be caused by protein misfolding
and retention in the endoplasmic reticulum because a
reduced incubation temperature was able to partially rescue
their expression and function; however, the loss of function
could not be explained by an increase of ubiquitylation of
TRPM4 protein.
Roles of TRPM4 in Cardiac Function
The localization and role of the TRPM4 channel in the heart is
still not completely understood. The fact that the pathogenic
TRPM4 variant E7K, among others, leads to conduction
disorders8 and that immunoreactivity was observed in Purk-
inje ﬁbers of the bovine heart9 strongly suggest that the
A
B
D
C
Figure 3. ECGs of patients harboring TRPM4 variants. A, ECG of a girl aged 14 years showing
severe bradycardia caused by complete atrioventricular block, with narrow QRS complexes (heart
rate 37 beats/min, QRS complex 69 ms). B, ECG in a man aged 45 years showing atrioventricular
block type 1 (PR interval 240 ms) associated with an incomplete left bundle branch block (RS pattern
in right precordial leads, RS pattern in left precordial leads, QRS complex 110 ms, QRS axis 15°). C,
ECG in a girl aged 7 years showing atrioventricular block type 1 (PR interval 280 ms) associated with
incomplete right bundle branch block (RSR0 pattern in right precordial leads, QRS complex 94 ms,
QRS axis 135°). D, ECG in a man aged 47 years showing atrioventricular block type 1 (PR interval
220 ms) associated with incomplete left bundle branch block (RS pattern in right precordial leads, RS
pattern in left precordial leads, QRS complex 100 ms, QRS axis 35°). E, ECG in a girl aged 7 years
showing bradycardia caused by complete atrioventricular block with narrow QRS complex (heart rate
40 beats/min, QRS complex 80 ms). F, Holter ECG in a boy aged 6 months showing severe
bradycardia caused by complete atrioventricular block with narrow QRS complexes (heart rate
55 beats/min, QRS complex 65 ms). G, Holter ECG in a boy aged 2 years showing severe
bradycardia caused by 2/1 atrioventricular block with narrow QRS complexes (heart rate 40 beats/
min, QRS 80 ms).
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TRPM4 channel is expressed and plays an important role in
the cardiac conduction pathway. Furthermore, several stud-
ies9,28 have provided evidence of the expression and function
of TRPM4 in the atrial myocardium and mouse sinoatrial node
cells.29 Mathar et al14 recently recorded TRPM4 currents
from isolated ventricular myocytes using Trpm4 knockout
mice. These Ca2+-activated currents were found to prolong
the late phase of the mouse action potential.14 Interestingly,
the silencing of TRPM4 increased the b-adrenergic–
dependent inotropic response of the ventricles. The ECG
characteristics of Trpm4 knockout mice are controversial.
Mathar et al14 did not observe any difference in the standard
ECG parameters, whereas Demion et al30 reported prolonged
PR and QRS durations, reduced conduction times above and
below the His-bundle, and episodes of intermittent AVB. This
discrepancy may be related to the different genetic back-
grounds of the 2 different knockout mouse lines or other
methodological differences. Further studies using cardiac-
speciﬁc knockout combined with potent pharmacological
tools will help decipher the physiological role of TRPM4 in
heart.
To date, 4 studies8–11 have reported rare TRPM4
variants in patients and families with various types of
cardiac conduction disorders and BrS. The present study
further supports the role of this channel in cardiac
conduction, particularly in atrioventricular conduction;
therefore, we propose adding TRPM4 to the list of
candidate genes to be screened in patients with conduc-
tion disease and BrS.
Altered Expression With TRPM4 AVB Variants
Several disease-causing variants in ion channels have
helped unravel their role in physiology. The present work,
with identiﬁcation of 5 new variants observed in patients
with either congenital or childhood AVB, further strengthens
the signiﬁcance of TRPM4 in the cardiac conduction
system. In analyzing the functional consequences of TRPM4
AVB variants (A432T and A432T/G582S), we determined a
reduction in cell membrane expression and function. A
possible explanation for such a loss of function could be
protein misfolding. To test our hypothesis about misfolding
of TRPM4 AVB variants, we performed temperature rescue
experiments. A similar temperature-dependent rescue of
misfolded protein was demonstrated previously in CFTR31
and hERG.32 Indeed, we observed a partial rescue of the
expression and function of the TRPM4 variants (A432T and
A432T/G582S) at lower temperature. To the best of our
knowledge, this report is the ﬁrst showing possible rescue
of TRPM4 variants with incubation at low temperature. This
ﬁnding also provides a clinical implication of using TRPM4
as a target for potent pharmacological chaperones in
rescuing loss-of-function variants.33 These misfolded pro-
teins could be tagged by ubiquitylation to be further
E
F
G
Figure 3. Continued.
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processed by the endoplasmic reticulum–associated protein
degradation pathway.34 Using a GST-tagged proteasome
subunit, we pulled down ubiquitylated fractions of TRPM4
WT and its variants; however, our data did not suggest
increased ubiquitylation as the cause of loss of function.
When the variant G582S was expressed individually,
A
B
Figure 4. Expression of TRPM4 WT and atrioventricular block variants. A, Western blots showing the expression of TRPM4 at the total
(left panel) and surface levels (right panel), with black and white arrowheads representing fully glycosylated and core-glycosylated forms
of TRPM4, respectively. B, Quantiﬁcation of the Western blots is shown as relative intensity of protein bands for both fully and core-
glycosylated forms of TRPM4 in each fraction. Quantiﬁcation done on 4 different Western blots. *P<0.05, **P<0.01, ***P<0.001. WT
indicates wild type.
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increased expression and current density was observed. Pre-
vious studies reported impairment of channel endocytosis
and an increase in SUMOylation for TRPM4 gain-of-function
mutants.8,9 We investigated the hypothesis that TRPM4
could be SUMOylated and the gain-of-function variant
(G582S) could be explained by increase in its SUMOylation
A
B
C
Figure 5. Whole-cell patch-clamp recording of WT and TRPM4 variants. A, Time course recording of
TRPM4 current. B, Individual current traces of each WT and TRPM4 variants recorded as plateau phases. C,
Quantiﬁcation of current density of WT and atrioventricular block variants. *P<0.05, **P<0.01, ***P<0.001
(WT, n=20; D198G, n=6; A432T, n=6; A432T/G582S, n=5; G582S, n=6; T677I, n=5; V921I, n=5; and E7K,
n=6). WT indicates wild type.
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status, as shown by Kruse et al.8 On the contrary, despite
using reliable positive controls in our study, we did not
observe any evidence of direct SUMOylation of either the
TRPM4 WT or G582S variant. We observed a stimulatory
effect on WT TRPM4 with the coexpression of the SUMO-
conjugating enzyme Ubc9, similar to Kruse et al,8 but this
increase was also observed when a catalytic inactive
mutant of Ubc9 was used. The existing disparity between
our studies and those previously reported by Kruse et al
illustrates the complexity of the regulation of TRPM4 and
its expression and trafﬁcking to the cell membrane;
however, the existence of indirect SUMOylation of TRPM4
via an ancillary protein may be possible. Our ﬁndings
suggest that the role of SUMOylation in the mechanism of
gain of expression and function of TRPM4 variants should
be reconsidered.
Both Gain and Loss of Function Were Observed
The observation that, as in BrS,11 these variants led to
either gain or loss of function is puzzling. Furthermore, the
mechanism by which these rare variants may reduce
impulse propagation in the conduction pathway is more
intriguing. A possibility is a mechanism analogous to the
supernormal excitability and conduction phenomenon35 that
has been described in atrioventricular conduction.36
Because TRPM4 generates a net inward depolarizing
current, assuming a tonic activity under resting conditions,
its increase would depolarize the resting membrane poten-
tial, whereas its reduction would hyperpolarize it. Conse-
quently, the availability of the excitable Na+ and Ca2+
channels would depend on TRPM4 activity. Both TRPM4-
dependent hyperpolarization and depolarization of the
resting membrane potential could reduce excitability and
conduction; however, no changes in the resting membrane
potential of ventricular cardiomyocytes were reported in the
study of Mathar et al,14 suggesting that this model should
be further investigated using cardiac tissues from WT and
Trpm4 knockout mice, with particular attention to its roles
in the conduction pathway.
Limitations of the Study
A main limitation of this study is that no direct causality
between the TRPM4 variants and congenital AVB could be
demonstrated. Whether or not a loss or gain of function is
related to the phenotype is still under debate. The small
pedigree size along with the sporadic nature of the presence
of the variants with the phenotype precludes any statistical
associations. In addition, the 2 TRPM4 variants that reveal a
functional impairment of the TRPM4 channel have been
identiﬁed in patients that also carry a mutation in other genes
A
B
C
Figure 6. Role of SUMOylation. Immunoprecipitation with anti-
RanGAP1 and anti-HA. A, Western blots on the upper panel show
immunoprecipitation of RanGAP1 and TRPM4, (B) whereas the
lower panels show their SUMOylation status. All samples were
run on the same gel and were blotted multiple times on the same
membrane with different antibodies. The lanes were rearranged
for clarity, and each experiment was performed 3 times. C,
Normalized current density of WT TRPM4 coexpressed with either
Ubc9 or the catalytically inactive mutant Ubc9*. *P<0.05 (WT,
n=8; Ubc9, n=5; and Ubc9*, n=5). WT indicates wild type.
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known to be involved in AVB (SCN5A, NKX2.5), thus it cannot
be excluded that the AVB phenotype might not just be related
to mutations in TRPM4. Finally, 3 variants identiﬁed did not
lead to any defects in our conditions (D198G, T677I, and
V921I). Future genetic studies with larger cohorts of patients
with different types of conduction disorders will help clarify
the precise role of TRPM4 in these phenotypes. In addition,
caution must be taken when extrapolating the results of
heterologous expression studies, as performed in this study,
to the in vivo situation. Further studies using knockout and
knock-in mouse models expressing similar variants are
required to better ascertain the proposed molecular and
cellular pathological mechanisms.
Conclusions
In conclusion, this study further supports the role of TRPM4
genetic variants in genetically determined cardiac conduction
disorders such as congenital and childhood AVB. Future
A
B
Figure 7. Rescue experiments of WT and TRPM4 variants. A, Western blot and quantiﬁcation showing
expression of WT and TRPM4 variants at the total and surface levels at 37°C and 28°C. Quantiﬁcation was
done on 3 different Western blots. B, Current density of WT and A432T at 37°C and 28°C recorded as the
plateau phase. *P<0.05, **P<0.01 (WT at 28°C, n=4; WT at 37°C, n=6; A432T at 28°C, n=6; and A432T at
37°C, n=6). Temp indicates temperature; WT, wild type.
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studies addressing the location and physiological and patho-
physiological roles of this channel in cardiac function are
necessary.
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